EcoDrugPlus

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSBMUG00000019690
Gene Symbol: PSMD2
3 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSBMUG00000024327
Gene Symbol: PSMD4
3 Cross references
287 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSBMUG00000012364
Gene Symbol: PSMC1
3 Cross references
316 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSBMUG00000010552
Gene Symbol: PSMC2
3 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSBMUG00000024510
Gene Symbol: PSMC3
3 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSBMUG00000015610
Gene Symbol: PSMC4
3 Cross references
199 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSBMUG00000006497
Gene Symbol: PSMC5
3 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSBMUG00000003949
Gene Symbol: PSMC6
3 Cross references
236 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSBMUG00000026011
Gene Symbol: PSMD1
3 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSBMUG00000010031
Gene Symbol: PSMD11
3 Cross references
283 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSBMUG00000009344
Gene Symbol: PSMD12
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSBMUG00000021856
Gene Symbol: PSMD13
3 Cross references
220 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).